Cite
MLA Citation
F. Spriano et al.. “THE ANTI‐CD25 ANTIBODY‐DRUG CONJUGATE CAMIDANLUMAB TESIRINE (ADCT‐301) PRESENTS A STRONG PRECLINICAL ACTIVITY BOTH AS SINGLE AGENT AND IN COMBINATION IN LYMPHOMA CELL LINES.” Hematological oncology, vol. 37, n.d., pp. 323–324. http://access.bl.uk/ark:/81055/vdc_100086209187.0x000049